Hyperthermia-triggered intracellular delivery of anticancer agent to HER2+ cells by HER2-specific affibody (ZHER2-GS-Cys)-conjugated thermosensitive liposomes (HER2+ affisomes)

Journal of Controlled Release

Volumn 153, Issue 2, 2011, Pages 187-194

  Smith, Brandon ^a,d   Lyakhov, Ilya ^b,e   Loomis, Kristin ^a,f   Needle, Danielle ^a   Baxa, Ulrich ^c   Yavlovich, Amichai ^a   Capala, Jacek ^b   Blumenthal, Robert ^a   Puri, Anu ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c SAIC FREDERICK INC   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e LLC   (United States)

^f GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Affibody; Drug delivery; Hyperthermia; Targeting; Triggerable liposomes

Indexed keywords

AFFIBODY; ANTI-CANCER AGENTS; ANTICANCER DRUG; BREAST CANCER TREATMENT; C-TERMINUS; CALCEIN; CELL COMPLEXES; CELL KILLING; CELL SURFACES; CELL VIABILITY; CELLULAR INTERACTION; CYTOSOLIC; CYTOSOLS; DOXORUBICIN; HUMAN EPIDERMAL GROWTH FACTOR; HYPERTHERMIA; IDENTICAL CONDITIONS; INTRACELLULAR DELIVERY; INTRACELLULAR UPTAKE; LOCALIZED DELIVERY; MOLE RATIO; PHOSPHATIDYL CHOLINE; RELEASE EXPERIMENTS; SPECIFIC BINDING; TARGETING; THERMOSENSITIVE LIPOSOMES; TRIGGERABLE LIPOSOMES;

AMINO ACIDS; CELL MEMBRANES; COMPLEXATION; CONFOCAL MICROSCOPY; DRUG DELIVERY; DRUG INTERACTIONS; EXPERIMENTS; HYPERTHERMIA THERAPY; LIPOSOMES; PHOSPHOLIPIDS;

CYTOLOGY;

CALCEIN; DIPALMITOYLPHOSPHATIDYLCHOLINE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2 ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; LIPOSOME; MACROGOL 2000; MALEIMIDE; RHODAMINE; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANTIGEN BINDING; ARTICLE; BREAST CANCER; CELL KILLING; CELL VIABILITY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG BINDING; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG UPTAKE; HEATING; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MEMBRANE PERMEABILITY; CELL SURVIVAL; DOXORUBICIN; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; LIPOSOMES; RECEPTOR, ERBB-2;

EID: 79960079535     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2011.04.005     Document Type: Article

References (28)

1. D. Needham, and M.W. Dewhirst The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors Adv. Drug Deliv. Rev. 53 2001 285 305 (Pubitemid 34024911)
2. P. Shum, J.M. Kim, and D.H. Thompson Phototriggering of liposomal drug delivery systems Adv. Drug Deliv. Rev. 53 2001 273 284 (Pubitemid 34024910)
3. M.B. Yatvin, J.N. Weinstein, W.H. Dennis, and R. Blumenthal Design of liposomes for enhanced local release of drugs by hyperthermia Science 202 1978 1290 1293 (Pubitemid 9154441)
4. D. Needham, G. Anyarambhatla, G. Kong, and M.W. Dewhirst A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model Cancer Res. 60 2000 1197 1201 (Pubitemid 30151982)
5. J.N. Weinstein, R.L. Magin, D.S. Zaharko, M.B. Yatvin, and R. Blumenthal Use of hyperthermia for selective localization of liposomal methotrexate in tumors Biophys. J. 25 1979 A291
6. A.H. Negussie, J.L. Miller, G. Reddy, S.K. Drake, B.J. Wood, and M.R. Dreher Synthesis and in vitro evaluation of cyclic NGR peptide targeted thermally sensitive liposome J. Control. Release 143 2010 265 273
7. A. Puri, K. Loomis, B. Smith, J.H. Lee, A. Yavlovich, E. Heldman, and R. Blumenthal Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic Crit. Rev. Ther. Drug Carrier Syst. 26 2009 523 580
8. T.M. Allen Liposomes. Opportunities in drug delivery Drugs 54 Suppl 4 1997 8 14 (Pubitemid 27487790)
9. V.P. Torchilin Liposomes as targetable drug carriers Crit. Rev. Ther. Drug Carrier Syst. 2 1985 65 115 (Pubitemid 16099051)
10. A. Puri, G. Kramer-Marek, R. Campbell-Massa, A. Yavlovich, S.C. Tele, S.B. Lee, J.D. Clogston, A.K. Patri, R. Blumenthal, and J. Capala HER2-specific affibody-conjugated thermosensitive liposomes (affisomes) for improved delivery of anticancer agents J. Liposome Res. 18 2008 293 307
11. F. Alexis, P. Basto, E. Levy-Nissenbaum, A.F. Radovic-Moreno, L. Zhang, E. Pridgen, A.Z. Wang, S.L. Marein, K. Westerhof, L.K. Molnar, and O.C. Farokhzad HER-2-targeted nanoparticle-affibody bioconjugates for cancer therapy ChemMedChem 3 2008 1839 1843
12. J. Beuttler, M. Rothdiener, D. Muller, F.Y. Frejd, and R.E. Kontermann Targeting of epidermal growth factor receptor (EGFR)-expressing tumor cells with sterically stabilized affibody liposomes (SAL) Bioconjug. Chem. 20 2009 1201 1208
13. J. Lofblom, J. Feldwisch, V. Tolmachev, J. Carlsson, S. Stahl, and F.Y. Frejd Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications FEBS Lett. 584 2010 2670 2680
14. A. Orlova, V. Tolmachev, R. Pehrson, M. Lindborg, T. Tran, M. Sandstrom, F.Y. Nilsson, A. Wennborg, L. Abrahmsen, and J. Feldwisch Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors Cancer Res. 67 2007 2178 2186 (Pubitemid 46424237)
15. K. Loomis, B. Smith, Y. Feng, H. Garg, A. Yavlovich, R. Campbell-Massa, D.S. Dimitrov, R. Blumenthal, X.D. Xiao, and A. Puri Specific targeting to B cells by lipid-based nanoparticles conjugated with a novel CD22-ScFv Exp. Mol. Pathol. 88 2010 238 249
16. B.N. Ames, and D.T. Dubin The role of polyamines in the neutralization of bacteriophage deoxyribonucleic acid J. Biol. Chem. 235 1960 769 775
17. S.S. Rawat, J. Eaton, S.A. Gallo, T.D. Martin, S. Ablan, S. Ratnayake, M. Viard, V.N. KewalRamani, J.M. Wang, R. Blumenthal, and A. Puri Functional expression of CD4, CXCR4, and CCR5 in glycosphingolipid-deficient mouse melanoma GM95 cells and susceptibility to HIV-1 envelope glycoprotein-triggered membrane fusion Virology 318 2004 55 65 (Pubitemid 38234261)
18. I. Lyakhov, R. Zielinski, M. Kuban, G. Kramer-Marek, R. Fisher, O. Chertov, L. Bindu, and J. Capala HER2- and EGFR-specific affiprobes: novel recombinant optical probes for cell imaging Chembiochem 11 2010 345 350
19. D.F. Nellis, S.L. Giardina, G.M. Janini, S.R. Shenoy, J.D. Marks, R. Tsai, D.C. Drummond, K. Hong, J.W. Park, T.F. Ouellette, S.C. Perkins, and D.B. Kirpotin Preclinical manufacture of anti-HER2 liposome-inserting, scFv-PEG-lipid conjugate. 2. Conjugate micelle identity, purity, stability, and potency analysis Biotechnol. Prog. 21 2005 221 232 (Pubitemid 40218492)
20. S.B. Lee, M. Hassan, R. Fisher, O. Chertov, V. Chernomordik, G. Kramer-Marek, A. Gandjbakhche, and J. Capala Affibody molecules for in vivo characterization of HER2-positive tumors by near-infrared imaging Clin. Cancer Res. 14 2008 3840 3849
21. A.C. Steffen, M. Wikman, V. Tolmachev, G.P. Adams, F.Y. Nilsson, S. Stahl, and J. Carlsson In vitro characterization of a bivalent anti-HER-2 affibody with potential for radionuclide-based diagnostics Cancer Biother. Radiopharm. 20 2005 239 248 (Pubitemid 41003829)
22. R. Zielinski, I. Lyakhov, A. Jacobs, O. Chertov, G. Kramer-Marek, N. Francella, A. Stephen, R. Fisher, R. Blumenthal, and J. Capala Affitoxin-a novel recombinant, HER2-specific, anticancer agent for targeted therapy of HER2-positive tumors J. Immunother. 32 2009 817 825
23. H. Wallberg, and A. Orlova Slow internalization of anti-HER2 synthetic affibody monomer 111In-DOTA-ZHER2:342-pep2: implications for development of labeled tracers Cancer Biother. Radiopharm. 23 2008 435 442
24. K.M. Laginha, E.H. Moase, N. Yu, A. Huang, and T.M. Allen Bioavailability and therapeutic efficacy of HER2 scFv-targeted liposomal doxorubicin in a murine model of HER2-overexpressing breast cancer J. Drug Target. 16 2008 605 610
25. G. Haran, R. Cohen, L.K. Bar, and Y. Barenholz Transmembrane ammonium-sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases Biochim. Biophys. Acta 1151 1993 201 215 (Pubitemid 23283973)
26. A. Gabizon, R. Catane, B. Uziely, B. Kaufman, T. Safra, R. Cohen, F. Martin, A. Huang, and Y. Barenholz Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes Cancer Res. 54 1994 987 992 (Pubitemid 24085451)
27. A. Gabizon, H. Shmeeda, and Y. Barenholz Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies Clin. Pharmacokinet. 42 2003 419 436 (Pubitemid 36649037)
28. R.T. O'Donnell, S.M. Martin, Y. Ma, W.C. Zamboni, and J.M. Tuscano Development and characterization of CD22-targeted pegylated-liposomal doxorubicin IL-PLD Invest. New Drugs 28 2010 260 267